Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 50 Carcinoma, Non-Small-Cell Lung 36 Ovarian Neoplasms 35 Stomach Neoplasms 32 Esophageal Neoplasms 29 Uterine Cervical Neoplasms 21 Esophageal Squamous Cell Carcinoma 19 Fallopian Tube Neoplasms 16 Lung Neoplasms 13 Carcinoma, Ovarian Epithelial 13 Neoplasms 9 Head and Neck Neoplasms 9 Carcinoma, Squamous Cell 9 Triple Negative Breast Neoplasms 8 Recurrence 8 Neoplasm Metastasis 6 Endometrial Neoplasms 6 Advanced Gastric Cancer 6 Squamous Cell Carcinoma of Head and Neck 5 Pancreatic Neoplasms 5 Nasopharyngeal Neoplasms 5 Hypopharyngeal Neoplasms 4 Oropharyngeal Neoplasms 3 Nasopharyngeal Carcinoma 3 Mouth Neoplasms 3 Melanoma 3 Laryngeal Neoplasms 3 Carcinoma 3 Anus Neoplasms 3 Adenocarcinoma Of Esophagus 3

Interventions

dehydroftorafur 1 Taxes 1 Radiotherapy, Intensity-Modulated 1 Radiation 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Fluorouracil 1 Cisplatin 1 Chemoradiotherapy 1 Carboplatin 1 Capecitabine 1 1,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Anal Canal Carcinoma × Paclitaxel × Clear all

NCT02560298 2023-06-22

InterAACT

Eastern Cooperative Oncology Group

Phase 2 Unknown

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡